

Review Article

Structural–functional brain changes in depressed patients during and after electroconvulsive therapy

Yrondi A, Péran P, Sauvaget A, Schmitt L, Arbus C. Structural–functional brain changes in depressed patients during and after electroconvulsive therapy: a systematic review of magnetic resonance imaging studies.

Objectives: Electroconvulsive therapy (ECT) is a non-pharmacological treatment that is effective in treating severe and treatment-resistant depression. Although the efficacy of ECT has been demonstrated to treat major depressive disorder (MDD), the brain mechanisms underlying this process remain unclear. Structural–functional changes occur with the use of ECT as a treatment for depression based on magnetic resonance imaging (MRI). For this reason, we have tried to identify the changes that were identified by MRI to try to clarify some operating mechanisms of ECT. We focus to brain changes on MRI [structural MRI (sMRI), functional MRI (fMRI) and diffusion tensor imaging (DTI)] after ECT.

Methods: A systematic search of the international literature was performed using the bibliographic search engines PubMed and Embase. The research focused on papers published up to 30 September 2015. The following Medical Subject Headings (MESH) terms were used: electroconvulsive therapy AND (MRI OR fMRI OR DTI). Papers published in English were included. Four authors searched the database using a predefined strategy to identify potentially eligible studies.

Results: There were structural changes according to the sMRI performed before and after ECT treatment. These changes do not seem to be entirely due to oedema. This investigation assessed the functional network connectivity associated with the ECT response in MDD. ECT response reverses the relationship from negative to positive between the two pairs of networks.

Conclusion: We found structural–functional changes in MRI post-ECT. Because of the currently limited MRI data on ECT in the literature, it is necessary to conduct further investigations using other MRI technology.

**Antoine Yrondi^{1,2},
 Patrice Péran²,
 Anne Sauvaget^{3,4},
 Laurent Schmitt¹,
 Christophe Arbus^{1,2}**

¹Psychiatric Department, CHU Toulouse-Purpan, Toulouse, France; ²Toulouse NeuroImaging Center, ToNIC, University of Toulouse, Inserm, UPS, France; ³Addictology and Liaison Psychiatry Department, CHU Nantes, 'Neuromodulation Unit in Psychiatry', Nantes, France; and ⁴EA 4275 SPHERE 'Methods for Patients-Centered Outcomes & Health Research', Faculty of Pharmaceutical Sciences, Université Nantes, Nantes, France

Keywords: depression; depressive disorder; electroconvulsive therapy; magnetic resonance imaging

Dr. Antoine Yrondi, Service de psychiatrie et psychologie médicale, CHU Toulouse-Purpan, 330 avenue de Grande Bretagne, 31059 Toulouse, France.

Tel: +33 5 34 55 75 37;

Fax: +33 5 34 55 75 32;

E-mail: antoineyrondi@gmail.com

Accepted for publication October 25, 2016

First published online November 23, 2016

Summations

- In structural magnetic resonance imaging (sMRI), there are higher amygdala and hippocampus volumes post-electroconvulsive therapy (ECT).
- In functional MRI (fMRI), there is a positive correlation between brain networks.
- ECT in depressive disorder seems to be associated with an increase of fractional anisotropy in dorsal fronto-limbic circuits.

Considerations

- The studies had small sample sizes.
- The studies presented do not take into account new ECT techniques such as focal electrically administered seizure therapy (FEAST).
- No study reported the role of an effective ECT session in brain structure and function

Introduction

One of the main indications for ECT are mood disorders, which include depressive episodes in unipolar (1,2) or bipolar depression and depressive decompensation of schizoaffective disorder, catatonia and manic episodes (3).

In a review by Loo (4), ECT was shown to be effective in 50–60% of patients with treatment-resistant depression. The author also noted an improvement in the quality of life in 87% of cases after treatment, and 78% of patients maintained this improvement 6 months after treatment.

Also, in patients presenting a depression [major depressive disorder (MDD)] without any criterion of resistance, ECT shows higher efficiency than antidepressants. A meta-analysis compared the ECT with the group of antidepressants including tricyclic antidepressants (TCA), monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors. The comparison of ECT versus antidepressants in general indicates a significant superior effect of ECT (association $\chi^2 = 51.88$, $df = 1$, $p < 0.001$). The chance of response with ECT is about four times greater than with the antidepressant drugs [odds ratio (OR) 3.72; 95% confidence interval (CI) 2.60, 5.32]. Patients receiving real ECT have nearly three more chances of a positive response than patients using TCA (OR 2.99; 95% CI 1.91, 4.71). A positive response with ECT is approximately six times greater than with MAOIs (OR 6.13; 95% CI 3.82, 9.83) (5).

The aim of ECT is to induce generalised therapeutic brain stimulation using a current delivered by transcranial electrodes.

After general anaesthesia and muscle relaxants, a short-type pulse current is used. Two types of positions can be achieved, namely bitemporal and unilateral; however, bitemporal has greater efficiency (3).

In Europe, two sessions a week are usually performed to obtain a good compromise between therapeutic effects and adverse cognitive effects (3,6–10). In USA, three sessions a week are performed to obtain quicker results. There would be no difference in the number of sessions of ECT to achieve. So the time, in weeks, would be shorter for the ‘thrice weekly’ group (11,12).

The number of sessions during an ECT treatment varies depending on the severity of depression and on the clinical response. Remission is expected after an

average of eight sessions of bilateral (BL) ECT (3). Treatment should be prolonged until complete remission is achieved.

Although the efficacy of ECT has been demonstrated to treat MDD (3,13) the brain mechanisms underlying this process remain unclear (14).

Various hypotheses can explain the operation of this treatment. The first hypothesis shows that ECT increases the neurobiological levels of serotonin, dopamine, norepinephrine and acetylcholine, as well as opioid and gamma-aminobutyric acid (GABA) activity (15). ECT reduces the D2 receptor binding potential of dopamine in the anterior cingulate cortex (16). It also diminishes the binding potential of 5-HT1A receptors in the anterior cingulate cortex, the frontal region of the orbitofrontal cortex, the amygdala and the hippocampus (17,18).

The second hypothesis is that ECT increases GABAergic action that diminishes excitation (19). And the third hypothesis is that ECT also affects neurogenesis, which has been demonstrated in animals with an increased expression in hippocampal brain derived neurotrophic factor serum levels (20–22). Several studies, including animal models of depression, have shown that ECT induces neurotrophic action on the hippocampus (increased neurogenesis and synaptogenesis and proliferation of glial cells) (20,23). Some work has highlighted the neuroplasticity mechanisms following an ECT treatment in regions of interest such as the hippocampus (24–26).

Neuroimaging data have revealed a multitude of regions and networks involved in depression that reflect the complexity and diversity of depressive states, both in unipolar and bipolar depression. These studies allowed the identification of a wide cortico-limbic network, including the following:

- The hippocampus, which is involved in memory, emotion or stress (27).
- The amygdala, which plays a role in emotions and in anxiety (28).
- The dorsolateral, ventrolateral and medial prefrontal cortices, which are involved in attentional processes, working memory and in decision making (29).
- The anterior cingulate cortex, which is involved in the motivational system.
- The basal ganglia, which play a role in learning routine procedures.

The motor slowing and cognitive disorders observed in depressed people may be due to disturbances in the cortico-limbic system (30).

At the neuroanatomical level, the major neural systems for understanding the pathophysiology of depression include those involved in the processing and regulation of emotion and rewards. These systems are altered in depression. They include subcortical systems involved in emotion and reward processes (the amygdala and the ventral striatum); the medial prefrontal cortex and the anterior cingulate gyrus are involved in processing and automatic or implicit emotion regulation, and the lateral prefrontal cortical system (prefrontal cortex and lateral dorsal lateral ventral) is involved in cognitive control and voluntary or forced emotion regulation (31).

These regions can be conceptualised as a medial prefrontal limbic network including the amygdala, anterior cingulate gyrus and the medial prefrontal cortex, which is modulated by serotonergic neurotransmission (32–34) and a rewards network centred on the ventral striatum in the interconnection with the medial prefrontal cortex and the orbitofrontal cortex, which is modulated by dopamine (35).

Neuroimaging studies (36–40) have shown functional abnormalities of those neural systems in adults with MDD.

A meta-analysis (41) of the neuroimaging of adults with depressive episodes identified a network focused on the dorsolateral prefrontal cortex and the most dorsal regions of the anterior cingulate gyrus, which show decreased activity in the idle state during depression (improved by the treatment). A second network, centred on the medial prefrontal cortex and subcortical regions, is hyperactivated by emotional stimuli in depression (improved with treatment). This meta-analysis provides evidence that there is increased activity of the neural system involved in processing emotions (amygdala and medial prefrontal cortex) and decreased activity of the neural system involved in emotion regulation (dorsolateral prefrontal cortex).

To our knowledge, there are three reviews (42–44) about the neuroimaging and ECT. These previous studies focus on systematic reviews of all neuroimaging techniques and not on a specific study of MRI and these studies consider different kind of patients. Bolwig's review did not target depressions in particular, Zhuo's work focused only on unipolar depression and Abbott et al. described only longitudinal studies of neuroimaging and not specifically the MRI in depression. To our knowledge, there is no review focusing only on the MRI [structural magnetic resonance imaging (MRI), functional MRI (fMRI) and diffusion tensor imaging (DTI)].

That is why we have tried to identify the changes that were identified by MRI to try to clarify some operating mechanisms of ECT and we have tried to identify the effect of electrode placement on neuroplasticity.

Materials and methods

A systematic search of the international literature was performed using the bibliographic search engines PubMed and Embase. The research focused on papers published up to 30 September 2015. The following Medical Subject Headings (MESH) terms were used: electroconvulsive therapy AND (MRI OR fMRI, OR DTI) AND depression. We also used the 'related articles' of PubMed, the bibliography lists, conference abstracts and Google Scholar to identify additional papers. Only papers published in English were included.

Four authors (A.Y., P.P., L.S. and C.A.) searched the database using a predefined strategy to identify potentially eligible studies. First independently and then jointly, these four authors selected studies based on summaries. All online abstracts were reviewed, and full-text papers were retrieved where relevant. This search procedure followed the PRISMA criteria (preferred reporting items for systematic reviews and meta-analyses) (45). Figure 1 summarises the organisational structure of the literature research strategy and the process used for selecting studies.

Results

General presentation of the results

We identified 24 studies including three reviews. These studies are on sMRI and fMRI.

sMRI (see Table 1). Table 1 There are 13 studies which are interested in morphological modifications (26,46–57).

Only two studies show no change (53,55).

In different studies, MRIs are performed between 2 h and 6 months after ECT.

There were structural changes according to the sMRI performed before and after ECT treatment. Early studies show changes in the white matter (57).

In the T1 and T2 sequences, there is an immediate increase in volume of the hippocampus and amygdala after ECT (26,50). Second MRIs are performed within 7 days of ECT. There is an increase of subgenual anterior cingulate gyrus as well as right anterior cingulate gyrus (47,49). For these studies, MRIs are performed between 20 days and 3 months after ECT.




Fig. 1. Flowchart of the search process. DTI, diffusion tensor imaging; MRI, magnetic resonance imaging.

Furthermore, there is an increase of grey matter volume (GMV) in insula and posterior superior temporal cortex (1 week after ECT) (48). These changes do not seem to be entirely due to oedema, as there is no visible modification of these structures on T2 relaxation time. Indeed, there was no significant change in MRI T2 relaxation time with ECT in any of the ROIs studied (thalamus, hippocampus, medial temporal lobe grey matter, medial temporal lobe white matter and dorsolateral frontal cortex) in the most recent studies (53). Past studies have hypothesised that ECT produces damage to the blood–brain barrier resulting in the brain oedema (58). Brain oedema could be detectable by MRI T1 and T2 relaxation times. Oedema is often visible on MRI, and they found no evidence, 2h after ECT, of oedema in the hippocampus on T2-weighted fluid-attenuated inversion recovery images. These data are not in favour of oedema, contrary to the findings of earlier studies (53,55,56). The volume of the hippocampus, at baseline, seems indicative of response to ECT (46). Moreover, a smaller pretreatment regional GMV of the right inferior frontal gyrus seems to be correlated with a faster speed of response. A smaller

regional GMV of the left inferior frontal gyrus seems to be correlated with higher remission rates (59). One study shows that there is an absence of persistent structural change (54). Joshi et al. show that lead placement is not shown to significantly influence changes in volume occurring with ECT for the left or right hippocampus or amygdala (46). Bouckaert et al. (48), in a *post hoc* analysis, show the morphometric results remained apparently unchanged when they exclude the four patients in whom right unilateral (RUL) ECT failed and who were switched to BL ECT. Although they find a significant [$p < 0.05$ after family wise errors (FWE) correction] GMV increase only in the right hemisphere (ipsilateral to the stimulation side), they show a GMV increase in both hemispheres using a less conservative uncorrected statistical parametric mapping (SPM) threshold of $p < 0.001$ (cluster-level $p < 0.05$ after FWE correction). BL ECT increases in GMV post-ECT are therefore probable, but these are most pronounced on the right side.

Dukart et al. (49) show that RUL ECT is correlated with regional increases in local GMV only in the right hemisphere and restricted to (1) the hippocampus, amygdala and anterior temporal pole, (2) the

Structural–functional brain changes in depressed patients during ECT

Table 1. Structural magnetic resonance imaging (MRI)

Studies	Number of patients	Characteristics	Time since ECT	Analysis	Result
Joshi et al. (46)	43 patients; 32 controls	32 RUL, 9 mixed RUL and bilateral, 2 bilateral Brief pulse Titration method Mean \pm SD = 11.45 \pm 3.21	T1: 24 h before ECT, T2: 24 h after 3rd ECT; T3: 1 week after ECT	General linear model Focus: hippocampal and amygdala segmentation 3 T MRI	ECT: structural plasticity in the hippocampus and amygdala Volume deficits normalise towards controls values Volume of the hippocampus at baseline: predictive of subsequent clinical outcome
Ota et al. (47)	15	Titration method brief pulse	13.1 \pm 19.1 days before ECT 9.0 \pm 14.6 after last ECT	VBM investigation ROI analysis hippocampus, amygdala, and rostral and caudal ACC T1	Increases in the volume of brain structures after ECT treatment: bilateral inferior temporal cortices, hippocampi and para-hippocampi, right subgenual anterior cingulate gyrus and right anterior cingulate gyrus
Bouckaert et al. (48)	28	RUL (4 patients are switched to bitemporal ECT) Dose titration, brief pulse 11.2 \pm 4 sessions of ECT	T1: 1 week before ECT T2: 1 week after ECT	VBM whole-brain analysis MRI 3 T	Righthemispheric grey matter volume increase: caudate nucleus, medial temporal lobe (including hippocampus and amygdala), insula and posterior superior temporal cortex
Dukart et al. (49)	No-ECT: 24 ECT: 10 Controls: 21	RUL 3 times a week. Brief pulse	T1: before ECT T2: 3 months after ECT T3: 6 months after ECT	Whole-brain analysis ROI analysis MRI: 1.5 T	Right unilateral ECT: correlated with regional increases in local GMV only in the right hemisphere and restricted to: the hippocampus, amygdala, and anterior temporal pole the insula; and the subgenual cortex
Abbot et al. (50)	MDD: 19 Controls: 20	RUL: 17 Bitemporal: 2–3 times weekly	Before and after ECT	Whole-brain Segmentation MRI: 3 T	ECT response is associated with increased hippocampus volume
Tendolkar et al. (51)	15	Bitemporal Brief pulse Stimulation max. 1008 mC 10 ECT	Before and after ECT	ROI: hippocampal and amygdala volume 1.5 T MRI	Hippocampus and amygdala show increased volume after ECT without evidence of a change in global brain volume
Nordanskog et al. (26), Nordanskog et al. 2013	12	10 RUL 2 bitemporal Brief pulse Dosage 10 ECT	Before ECT (T1) <7 days (T2), 168 days (T3) and 364 days (T4)	ROI: hippocampal volumes 3 T MRI	Volume increase between T1 and T2
Kunigiri et al. (53)	15	10 bitemporal 5 RUL Titration method	Before the first ECT and 2 h after 2nd	The T(2) relaxation time was measured bilaterally in the thalamus, hippocampus, medial temporal lobes and dorsolateral frontal cortex by a blind rater MRI 1.5 T	There is no change in T2 relaxation time after 2nd ECT
Szabo et al. (57)	10	8 RUL, 1 bitemporal et 1 RUL/bitemporal titration method Brief pulse 10–29 ECT	After ECT	ROI: head and body of the hippocampus 1.5 T MRI	Absence of persistent structural change
Girish et al. (55)	5	5 RUL Titration method	Before the first ECT and 2 h after 2nd	MRI T(2) relaxation times were measured in the hippocampus and thalamus bilaterally	There was no change in the T2 relaxation time after 2nd ECT
Dielh et al. 1994	6	RUL Brief pulse	1–2 days before ECT, 30 h after the first ECT and 2 h after the second ECT	ROI: medial temporal lobe (white and grey substances) and thalamus	The T2 relaxation time post-ECT increased the right and left thalamic oedema
Coffey et al. (57)	36	RUL and bitemporal	After ECT	MRI 1.5 T	Changing white matter in 86% of cases MRI

ACC, anterior cingulate cortex; CGA, global cortical atrophy; ECT, electroconvulsive therapy; GMV, grey matter volume; MDD, major depressive disorder; MRI, magnetic resonance imaging; RUL, right unilateral; ROI, region of interest; T, Tesla T1, Time 1; VBM, voxel-based morphometry; WMH, white matter hyperintensities.

insula and (3) the subgenual cortex. Local GMV decreases associated with ECT were noted in the right middle and inferior frontal cortex and premotor regions. Except for the insula, these results are

significant after adjustment for the effects of drug treatment.

Nordanskog et al. (26) do not show any correlation between the type of stimulation (unilateral or BL)

Table 2. Functional magnetic resonance imaging (MRI)

Studies	Number of patients	Characteristics	Time since ECT	Analysis	Result
Wei et al. (63)	11 MDD 15 controls	bifrontal	12–24 h before ECT 24–72 h after ECT	Voxel-mirrored homotopic connectivity (VMHC) method resting-state functional images MRI 3T	ECT selectively modulated interhemispheric functional coordination in depression patients
Abbot et al. (50)	MDD: 19 Controls: 20	RUL: 17 Bitemporal: 2–3 times weekly	Before and after ECT	Whole-brain Segmentation MRI: 3T	ECT response is associated with increased hippocampal functional connectivity
Abbot et al. (62)	12	10 RUL 2 Bitemporal Brief pulse 11 ECT	T1: before ECT T2: after ECT	Four networks were affected in MDD: the subcallosal cingulate gyrus, the default mode, the dorsal lateral prefrontal cortex, and the dorsal medial prefrontal cortex	ECT T1 vs T2: ECT remitters had increased functional network connectivity between the posterior default mode/DMPFC and the posterior default mode/left DLPFC
Beall et al. (65)	6 MDD	Bitemporal Brief pulse Dosage 9 ECT	T0: before ECT T1: 1 to 3 weeks	fMRI tasks: working memory and emotional tasks. ROI to ROI and activation Resting-state fMRI ROI to ROI	ECT T1 vs T2: orbital frontal cortex activation changes were correlated with depression rating changes in the emotional task. The results did not survive multiple comparisons corrected in the working memory task and resting-state fMRI
Perrin et al. (64)	9 MDD	Bitemporal Brief pulse 8 ECT	Before and after ECT	An unbiased, data-driven analysis of treatment effects and the identification of a target region of interest. This region was then used to determine the associated functional brain networks	ECT T1 vs T2: connectivity decreased in the left DLPFC; Using this region as a seed, seed-voxel correlations revealed decreased connectivity in the anterior cingulate, medial frontal cortex, bilateral DLPFCs, and left parietal region.
Christ et al. (66)	11 MDD	7 RUL 4 bitemporal Brief pulse 12 ECT	T1: before ECT T2: after 8 ECT T3: after remission (end of treatment)	fMRI tasks: auditory stimulation paradigm Image analysis: voxel-wise (whole-brain) analysis; ROI to assess activation intensities	ECT T1 vs T3: in the voxel-wise analysis, there was decreased activation in the frontal, temporal, parietal, occipital and anterior cingulate cortices

DLPFC, dorsolateral prefrontal cortex; DMPFC, dorsomedial prefrontal cortex; ECT, electroconvulsive therapy; fMRI, functional MRI; MRI, magnetic resonance imaging; RUL, right unilateral; ROI, region of interest; T, Tesla T1, Time 1.

and structural modification. The increase in volume of the left hippocampus [T1 (before ECT) vs T2 (<7 days after ECT)] was positively correlated to the number of ECT treatments ($r = 0.67$, $p < 0.05$).

A review(44) concerning sMRI highlights an increase of the hippocampal volume at the 1 week post-ECT imaging assessment. But, hippocampal volume had decreased back to the pre-ECT volumes upon longer follow-up assessments at 180 and 365 days and was not correlated with antidepressant response or side effects (Table 1).

Moreover, it seems that moderate or severe white matter hyperintensities before ECT was associated with higher mortality and global cortical atrophy was possibly associated with cognitive decline upon follow-up. On the other hand, depressed elderly patients with white matter hyperintensities who receive BL ECT are at increased risk of transient cognitive impairment (60,61).

fMRI (see Table 2). Table 2 There are six studies which are interested in functional modifications (50,62–66). All studies show changes in fMRI.

This investigation assessed the resting-state functional network connectivity associated with the ECT response in MDD. Abbott et al. show that ECT response reverses the relationship from negative

to positive between the two pairs of networks: the relationship from negative to positive between the posterior default mode and the dorsomedial prefrontal cortex, and between the posterior default mode and the dorsolateral prefrontal cortex (DLPFC) (62).

There is a consistent increase in connectivity to the right DLPFC and posterior cingulate cortex after ECT during working memory and affective tasks (65). In addition, there is a decrease in activity in the frontal, temporal, parietal, occipital gyrus and anterior lobes after ECT using auditory stimuli (66). Right hippocampal connectivity seems to be increased (normalised) after the ECT series and correlated with depressive symptom reduction (50). Christ et al (66) use tonal stimulation to assess the impact of ECT treatment on auditory related networks. They show that depressed patients reduced activation of several cortical areas during ECT course. This indicates that ECT may elicit an unspecific inhibitory effect on neuronal activity. Moreover, sensory perception is still altered post-ECT, even if ECT is effective.

These two studies (65,66) are resumed in the review of Abbott (44).

Another review (43) highlights fMRI studies. In this review, many studies point to an increased

Structural–functional brain changes in depressed patients during ECT

Table 3. Diffusion tensor imaging (DTI)

Studies	Number of patients	Characteristics	Time since ECT	Analysis	Result
Jorgensen et al. (68)	MDD: 19	Bitemporal: 16 Switch to RUL: 3 Dosage	Before ECT (T1), One (T2) and four (T3) weeks after the series of ECT	DTI data: b-values 0 and 1,200 s/mm ² , 61 diffusion sensitising gradient directions MRI: 3 T T1w structural images (MPRAGE) using methods from the SPM5/VBM5 and SPM8/VBM8 toolboxes	Hippocampal and amygdala volume increased significantly at T2 and continued to be increased at T3 DLPFC exhibited a transient volume reduction at T2. DTI revealed a reduced anisotropy and diffusivity of the hippocampus at T2
Lyden et al. (67)	MDD: 20 Controls: 28	RUL: 16 Bitemporal: 4 Titration method	Before ECT, after second ECT, and at the end of the cure	DTI data: echo-planar sequence including 61 non-collinear, icosahedrally distributed directions, 10 b0 images and 55 axial slices (b = 0, 1,000 s/mm ² ; FOV: 24 cm, 96 × 96 matrix, 2.5 mm isotropic voxel size) MRI: 3 T Voxel-wise statistical analysis used validated TBSS workflows FSL's Randomise tool	Increases of FA in dorsal fronto-limbic circuits encompassing the anterior cingulum, forceps Minor and left superior longitudinal fasciculus between baseline and transition to maintenance therapy. Decreases in RD and MD were observed in overlapping regions and the anterior thalamic radiation

DLPFC, dorsolateral prefrontal cortex; DTI, diffusion tensor imaging; ECT, electroconvulsive therapy; FA, fractional anisotropy; FOV, field of view; FSL, FMRIB software library; MD, mean diffusivity; MDD, major depressive disorder; MRI, magnetic resonance imaging; MPRAGE, magnetization-prepared rapid acquisition with gradient echo; RD, radial diffusivity; RUL, right unilateral; TBSS, tract-based spatial statistic; VBM, voxel-based morphometry.

intrinsic connectivity in several neuronal networks implicated in different aspects of depression.

Wei et al. (63) do not show any correlation between the type of stimulation (unilateral or BL) and modification functional (Table 2).

DTI (see Table 3). Table 3 There are two studies using MRI DTI. ECT in depressive disorder seems to be associated with an increase of fractional anisotropy in dorsal fronto-limbic circuits encompassing the anterior cingulum, forceps minor and left superior longitudinal fasciculus between baseline and transition to maintenance therapy. And, it seems to be associated with a decrease in radial diffusivity and average diffusivity are observed in overlapping regions and the anterior thalamic radiation (67). Jorgensen et al. (68) show that hippocampal and amygdala volume increased significantly at 1 week after the series of ECT and continued to be increased at 4 weeks.

DLPFC exhibited a transient volume reduction at 1 week after the series of ECT.

DTI reveal a reduced anisotropy and diffusivity of the hippocampus at 1 week.

Discussion

This systematic review highlights brain structural and functional changes during treatment with ECT. The studies explored in this article can improve the understanding of the most effective therapeutic in MDD. This also allows to improve the understanding of the pathophysiology of depression. There are higher

amygdalae and hippocampus volumes post-ECT and, without this increase, there would be long-term oedema. It seems that there is an improvement in functional connectivity in some networks (between the posterior default mode and dorsal medial prefrontal cortex and posterior default mode and the dorsal lateral prefrontal cortex left). In the MRI performed before starting ECT and after ECT remission using auditory stimuli, there was a decrease in the temporal, parietal, occipital gyrus and anterior lobe activities. Moreover, low hippocampal volume and a large volume of grey matter of the inferior frontal gyrus seems to be markers of poor treatment response (46,59). There seems to be predictive of response to treatment. However, these results should be put into perspective, because the length of time of the scan after the last ECT varies significantly from one study to another. It is therefore difficult to generalise these results to all patients with ECT.

Our review complements three references (42–44) that are dedicated to all neuroimaging investigations, focusing on MRI. The results of our review seem coherent with the existing data of the science. The depressive disorder seems to have an echo on the median temporal lobe (in particular hippocampus and amygdala) (69). The antidepressant treatments seem to act on these structures, too. The action of the ECT, both at the morphological and structural level, could correspond to an antidepressant mechanism of action (70). Unlike the repetitive transcranial magnetic stimulation (rTMS) which seems to have a localised effect on fractional anisotropy (FA) values in the prefrontal white matter of the left hemisphere (side stimulated with rTMS) (71).

Moreover, the changes reported in these human studies go in the same direction as the animal data. Several studies, including animal models of depression, explain that ECT induce a neurotrophic effect on hippocampus and amygdala (20,23).

There were limits in these studies.

First, the limits are for sample sizes. Some of the studies had small sample sizes. The largest study included 36 patients. The small sample sizes (average sample of included studies) limit the ability to detect differences in whole-brain analyses and correlate with symptom improvement. Because patients who receive ECT are mostly patients with a certain level of severity and urgency, the possibility to perform several MRI studies is complicated.

Second, the limits are for ECT. Most studies are done with a unilateral placement of electrodes, or with mixed populations (unilateral and BL placement of electrodes). Only three studies were performed with a bipartite placement of electrodes (51,64,65) and only one with a bifrontal placement. It would therefore be of considerable interest to conduct a study to investigate the effect of electrode placement on brain plasticity after ECT (particularly taking into account new techniques such as FEAST). However, different parameters of ECTs, in addition to the electrode placement, have a role in the efficacy and tolerance of ECT (72). But it does not appear that these various parameters have been considered in the data analysis. Only the brief pulse current was used in all studies. We know that there are more cognitive side effects with a bipartite placement of electrodes than an unilateral placement in the right hemisphere (73,74). Therefore, it is possible that with different parameters, the brain structures involved are not the same or they do not have the same intensity. Indeed, the cognitive findings consistently indicate that electrode placement (RUL vs BL) is a more powerful determinant of short-term and long-term deficits than stimulus dosage. Higher stimulus intensity seems to be associated with greater impairment in a variety of acute (postictal) cognitive measures, and selective measures of anterograde amnesia during the week following ECT. But, BL ECT (independent of dosage) seems to result in more profound anterograde and retrograde amnesia during the week following ECT and greater retrograde amnesia at 2-month post-ECT follow-up. So, the effects of stimulus intensity on cognitive parameters wear off rapidly, whereas the effects of electrode placement are persistent. It is also noteworthy that, for both efficacy and cognitive effects, the degree to which electrical dosage exceeds the threshold (1 vs 2.5) is predictive of outcomes, but absolute electrical dosage has no such relations. Some studies show that the severity of cognitive

effects and efficacy of treatment conditions are fully dissociated. A number of studies highlight comparable therapeutic efficiency between RUL ECT with high stimuli intensity and BL ECT. But it would seem that the RUL is better tolerated (75–77). UltraBrief stimulus RUL ECT have a clear advantage over UB BL ECT in both cognitive and therapeutic outcomes (77). The use of an ultrabrief stimulus markedly reduces adverse cognitive effects, and when coupled with markedly suprathreshold RUL ECT, also preserves efficacy (74). There also seems to be a correlation between the individual threshold and the percentage reduction in Hamilton scores [-0.38 ($p = 0.05$)] (78). The evaluation of the data of neuroimaging post-ECT seems to be able to be only made according to these various parameters.

Third, the limits are for MRI methods. The studies presented do not take into account new ECT techniques, such as FEAST (79,80), which seem to be interesting in terms of their tolerance and effectiveness. Currently, there is only one study in SPECT imaging after a session of FEAST (81) which shows a much more focused action. It would be interesting to compare classical ECT with FEAST in terms of their relative clinical efficacy and safety, in particular at the cognitive level, and the impact on brain structures involved in mood and in cognition with MRI imaging techniques.

No study reported simultaneously the impact of an effective ECT session in brain structure and function. Currently, the exact operation of ECT in depression remains unclear. In a few studies, DTI imaging sequences were missing. These data would more precisely determine the connectivity that exists after ECT treatment. Similar to the studies of Parkinson's disease (82–84), multimodal MRI could help us improve our knowledge of ECT. The multimodal MRI is a combination of several quantitative magnetic resonance parameters sensitive to complementary tissue characteristics (i.e. volume atrophy, iron deposition and microstructural damage). These structural biomarkers could be associated to functional markers in the same exam (using resting-state fMRI). So, from a single MRI exam, we can measure several sequences [anatomical three-dimensional T1-weighted images, DTI, and resting-state fMRI] able to provide structural and functional brain indices. Even if DTI is conventionally used to evaluate white matter tracts and to measure the degree of anisotropy by calculating the FA, DTI could also be used to measure mean diffusivity (MD) in the grey matter reflecting microstructural integrity. In addition to classical structural markers of atrophy, MD can bring complementary information about grey matter

integrity. Indeed, an increase in MD and decreased fraction anisotropy reflect a progressive loss of barriers restricting the movement of water molecules in tissue compartments, which is associated with neuronal loss and myelin sheath degradation. Previous MRI studies investigating physiological aging (85), neurodegenerative diseases (82,86,87), or psychiatric diseases (88) showed the complementary aspect of atrophy markers and MD parameter. Another potential MRI technique is the quantification of mineral levels in the brain. MR relaxometry (T2*) is a sensitive method to evaluate the brain iron content *in vivo*. Iron accumulation has been implicated in the pathogenesis of many neurodegenerative diseases (83,89). They could be associated with functional imaging markers extracted from resting-state fMRI (e.g. connectivity strength of the default network mode). Thus, from a single MRI exam, we can measure structural and functional brain changes simultaneously. These imaging results reveal possible future research opportunities in studying the mechanism of action of ECT and the pathophysiology of depression. It seems important to move towards multimodal MRI studies in the future.

We found MRI works separately investigating structural and functional brain changes post-ECT. Because of the limits of previous studies discussed above, it is necessary to conduct investigations using multimodal MRI able to provide complementary aspects about the complex changes linked to ECT. These further studies could provide information concerning the structuro–functional modifications at different steps of the ECT therapy (after a single ECT, after an effective ECT, and after a whole ECT cure).

Acknowledgements

None. Authors' contributions: four authors (A.Y., P.P., L.S. and C.A.) searched the database using a predefined strategy to identify potentially eligible studies. First independently and then jointly, these four authors selected studies based on summaries. A.Y. and A.S. are co-writing the article based on data selected by A.Y., P.P., L.S. and C.A.

Financial Support

This research received no specific grant from any funding agency or from commercial or not-for-profit sectors.

Conflicts of Interest

None.

References

1. ANAES. Indications et modalités de l'électroconvulsivothérapie. Fédération Française de Psychiatrie, Société Française d'Anesthésie et de Réanimation, Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES); 1998.
2. BAGHAI TC, MÖLLER H-J. Electroconvulsive therapy and its different indications. *Dialogues Clin Neurosci* 2008;**10**: 105–117.
3. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* 2003;**361**:799–808.
4. LOO C. ECT in the 21st century: optimizing treatment: state of the art in the 21st century. *J ECT* 2010;**26**:157.
5. PAGNIN D, DE QUEIROZ V, PINI S, CASSANO GB. Efficacy of ECT in depression: a meta-analytic review. *J ECT* 2004;**20**: 13–20.
6. GANGADHAR BN, JANAKIRAMAIAH N, SUBBAKRISHNA DK, PRAVEEN J, REDDY AK. Twice versus thrice weekly ECT in melancholia: a double-blind prospective comparison. *J Affect Disord* 1993;**27**:273–278.
7. JANAKIRAMAIAH N, MOTREJA S, GANGADHAR BN, SUBBAKRISHNA DK, PARAMESHWARA G. Once vs. three times weekly ECT in melancholia: a randomized controlled trial. *Acta Psychiatr Scand* 1998;**98**:316–320.
8. LERER B, SHAPIRA B, CALEV A et al. Antidepressant and cognitive effects of twice- versus three-times-weekly ECT. *Am J Psychiatry* 1995;**152**:564–570.
9. TAYLOR S. Electroconvulsive therapy: a review of history, patient selection, technique, and medication management. *South Med J* 2007;**100**:494–498.
10. SVENSSON M, HALLIN T, BROMS J, EKSTRAND J, TINGSTRÖM A. Spatial memory impairment in Morris water maze after electroconvulsive seizures. *Acta Neuropsychiatr* 2016; 6231–10. DOI: <https://doi.org/10.1017/neu.2016.22>.
11. SISKIND D, CHARLSON F, SARAF S, SCHEURER R, LIE DC. Twice versus thrice weekly ECT in a clinical population: an evaluation of patient outcomes. *Psychiatry Res* 2012;**199**: 208–211.
12. CHARLSON F, SISKIND D, DOI SAR, MCCALLUM E, BROOME A, LIE DC. ECT efficacy and treatment course: a systematic review and meta-analysis of twice vs thrice weekly schedules. *J Affect Disord* 2012;**138**:1–8.
13. HUSAIN SS, KEVAN IM, LINNELL R, SCOTT AIF. Electroconvulsive therapy in depressive illness that has not responded to drug treatment. *J Affect Disord* 2004;**83**: 121–126.
14. HOY KE, FITZGERALD PB. Brain stimulation in psychiatry and its effects on cognition. *Nat Rev Neurol* 2010;**6**: 267–275.
15. RUDORFER M, HENRY M, SACKEIM H. Electroconvulsive therapy. In: Tasman A, Kay J, Lieberman JA editors *Psychiatry Therapeutics*. Chichester: John Wiley & Sons, 2003.
16. SAJO T, TAKANO A, SUHARA T et al. Electroconvulsive therapy decreases dopamine D₂ receptor binding in the anterior cingulate in patients with depression: a controlled study using positron emission tomography with radioligand [¹¹C]FLB 457. *J Clin Psychiatry* 2010;**71**:793–799.
17. SAJO T, TAKANO A, SUHARA T et al. Effect of electroconvulsive therapy on 5-HT_{1A} receptor binding in patients with depression: a PET study with [¹¹C]WAY 100635. *Int J Neuropsychopharmacol* 2010;**13**:785–791.
18. LANZENBERGER R, BALDINGER P, HAHN A et al. Global decrease of serotonin-1A receptor binding after

- electroconvulsive therapy in major depression measured by PET. *Mol Psychiatry* 2013;**18**:93–100.
19. SACKEIM HA. The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. *J ECT* 1999;**15**:5–26.
 20. CHEN F, MADSEN TM, WEGENER G, NYENGAARD JR. Repeated electroconvulsive seizures increase the total number of synapses in adult male rat hippocampus. *Eur Neuropsychopharmacol* 2009;**19**:329–338.
 21. MADSEN TM, TRESCHOW A, BENZON J, BOLWIG TG, LINDVALL O, TINGSTRÖM A. Increased neurogenesis in a model of electroconvulsive therapy. *Biol Psychiatry* 2000;**47**:1043–1049.
 22. SCOTT BW, WOJCIOWICZ JM, BURNHAM WM. Neurogenesis in the dentate gyrus of the rat following electroconvulsive shock seizures. *Exp Neurol* 2000;**165**:231–236.
 23. WENNSTRÖM M, HELSTEN J, TINGSTRÖM A. Electroconvulsive seizures induce proliferation of NG2-expressing glial cells in adult rat amygdala. *Biol Psychiatry* 2004;**55**:464–471.
 24. LEKWAUWA RE, MCQUOID DR, STEFFENS DC. Hippocampal volume as a predictor of short-term ECT outcomes in older patients with depression. *Am J Geriatr Psychiatry* 2005;**13**:910–913.
 25. LEKWAUWA R, MCQUOID D, STEFFENS DC. Hippocampal volume is associated with physician-reported acute cognitive deficits after electroconvulsive therapy. *J Geriatr Psychiatry Neurol* 2006;**19**:21–25.
 26. NORDANSKOG P, DAHLSTRAND U, LARSSON MR, LARSSON E-M, KNUTSSON L, JOHANSON A. Increase in hippocampal volume after electroconvulsive therapy in patients with depression: a volumetric magnetic resonance imaging study. *J ECT* 2010;**26**:62–67.
 27. BLUMBERG HP, KAUFMAN J, MARTIN A et al. Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. *Arch Gen Psychiatry* 2003;**60**:1201–1208.
 28. STONE VE, BARON-COHEN S, CALDER A, KEANE J, YOUNG A. Acquired theory of mind impairments in individuals with bilateral amygdala lesions. *Neuropsychologia* 2003;**41**:209–220.
 29. KOENIGS M, GRAFMAN J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. *Behav Brain Res* 2009;**201**:239–243.
 30. MAYBERG HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. *Br Med Bull* 2003;**65**:193–207.
 31. PHILLIPS ML, LADOUCEUR CD, DREVETS WC. A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. *Mol Psychiatry* 2008;**13**:829–833–857.
 32. BERTOLINO A, ARCIERO G, RUBINO V et al. Variation of human amygdala response during threatening stimuli as a function of 5-HTTLPR genotype and personality style. *Biol Psychiatry* 2005;**57**:1517–1525.
 33. HARIRI AR, DRABANT EM, MUNOZ KE et al. A susceptibility gene for affective disorders and the response of the human amygdala. *Arch Gen Psychiatry* 2005;**62**:146–152.
 34. HEINZ A, SMOLKA MN, BRAUS DF et al. Serotonin transporter genotype (5-HTTLPR): effects of neutral and undefined conditions on amygdala activation. *Biol Psychiatry* 2007;**61**:1011–1014.
 35. SCHULTZ W. Behavioral dopamine signals. *Trends Neurosci* 2007;**30**:203–210.
 36. DANNLOWSKI U, OHRMANN P, BAUER J et al. Amygdala reactivity to masked negative faces is associated with automatic judgmental bias in major depression: a 3 T fMRI study. *J Psychiatry Neurosci JPN* 2007;**32**:423–429.
 37. FALES CL, BARCH DM, RUNDLE MM et al. Altered emotional interference processing in affective and cognitive-control brain circuitry in major depression. *Biol Psychiatry* 2008;**63**:377–384.
 38. FU CHY, MOURAO-MIRANDA J, COSTAFREDA SG et al. Pattern classification of sad facial processing: toward the development of neurobiological markers in depression. *Biol Psychiatry* 2008;**63**:656–662.
 39. KEEDWELL PA, ANDREW C, WILLIAMS SCR, BRAMMER MJ, PHILLIPS ML. A double dissociation of ventromedial prefrontal cortical responses to sad and happy stimuli in depressed and healthy individuals. *Biol Psychiatry* 2005;**58**:495–503.
 40. SURGULADZE S, BRAMMER MJ, KEEDWELL P et al. A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. *Biol Psychiatry* 2005;**57**:201–209.
 41. FITZGERALD PB, LAIRD AR, MALLER J, DASKALAKIS ZJ. A meta-analytic study of changes in brain activation in depression. *Hum Brain Mapp* 2008;**29**:683–695.
 42. ZHUO C, YU C. Functional neuroimaging changes subsequent to electroconvulsive therapy in unipolar depression: a review of the literature. *J ECT* 2014;**30**:265–274.
 43. BOLWIG TG. Neuroimaging and electroconvulsive therapy: a review. *J ECT* 2014;**30**:138–142.
 44. ABBOTT CC, GALLEGOS P, REDISKE N, LEMKE NT, QUINN DK. A review of longitudinal electroconvulsive therapy: neuroimaging investigations. *J Geriatr Psychiatry Neurol* 2014;**27**:33–46.
 45. MOHER D, LIBERATI A, TETZLAFF J, ALTMAN DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;**6**:e1000097.
 46. JOSHI SH, ESPINOZA RT, PIRNIA T et al. Structural plasticity of the hippocampus and amygdala induced by electroconvulsive therapy in major depression. *Biol Psychiatry* 2015; March 5.
 47. OTA M, NODA T, SATO N et al. Effect of electroconvulsive therapy on gray matter volume in major depressive disorder. *J Affect Disord* 2015;**186**:186–191.
 48. BOUCKAERT F, DE WINTER F-L, EISEL L et al. Grey matter volume increase following electroconvulsive therapy in patients with late life depression: a longitudinal MRI study. *J Psychiatry Neurosci JPN* 2015;**40**:140322.
 49. DUKART J, REGEN F, KHERIF F et al. Electroconvulsive therapy-induced brain plasticity determines therapeutic outcome in mood disorders. *Proc Natl Acad Sci U S A* 2014;**111**:1156–1161.
 50. ABBOTT CC, JONES T, LEMKE NT et al. Hippocampal structural and functional changes associated with electroconvulsive therapy response. *Transl Psychiatry* 2014;**4**:e483.
 51. TENDOLKAR I, VAN BEEK M, VAN OOSTROM I et al. Electroconvulsive therapy increases hippocampal and amygdala volume in therapy refractory depression: a longitudinal pilot study. *Psychiatry Res* 2013;**214**:197–203.
 52. NORDANSKOG P, LARSSON MR, LARSSON E-M, JOHANSON A. Hippocampal volume in relation to clinical and cognitive outcome after electroconvulsive therapy in depression. *Acta Psychiatr Scand* 2014;**129**:303–311.
 53. KUNIGIRI G, JAYAKUMAR PN, JANAKIRAMAIAH N, GANGADHAR BN. MRI T(2) relaxometry of brain regions and cognitive

Structural–functional brain changes in depressed patients during ECT

- dysfunction following electroconvulsive therapy. *Indian J Psychiatry* 2007;**49**:195–199.
54. SZABO K, HIRSCH JG, KRAUSE M et al. Diffusion weighted MRI in the early phase after electroconvulsive therapy. *Neurol Res* 2007;**29**:256–259.
 55. GIRISH K, JAYAKUMAR PN, MURALI N, GANGADHAR BN, JANAKIRAMAIAH N, SUBBAKRISHNA DK. Ect and t(2) relaxometry: a static walter proton magnetic resonance imaging study. *Indian J Psychiatry* 2001;**43**:22–24.
 56. DIEHL DJ, KESHAVAN MS, KANAL E, NEBES RD, NICHOLS TE, GILLEN JS. Post-ECT increases in MRI regional T2 relaxation times and their relationship to cognitive side effects: a pilot study. *Psychiatry Res* 1994;**54**:177–184.
 57. COFFEY CE, FIGIEL GS, DJANG WT, CRESS M, SAUNDERS WB, WEINER RD. Leukoencephalopathy in elderly depressed patients referred for ECT. *Biol Psychiatry* 1988;**24**:143–161.
 58. SCOTT AI, DOUGLAS RH, WHITFIELD A, KENDELL RE. Time course of cerebra; magnetic resonance changes after electroconvulsive therapy. *Br J Psychiatry J Ment Sci* 1990;**156**:551–553.
 59. OUDEGA ML, VAN EXEL E, STEK ML et al. The structure of the geriatric depressed brain and response to electroconvulsive therapy. *Psychiatry Res* 2014;**222**:1–9.
 60. OUDEGA ML, DOLS A, ADELERHOF I et al. Contribution of white matter hyperintensities, medial temporal lobe atrophy and cortical atrophy on outcome, seven to twelve years after ECT in severely depressed geriatric patients. *J Affect Disord* 2015;**185**:144–148.
 61. OUDEGA ML, VAN EXEL E, WATTJES MP et al. White matter hyperintensities and cognitive impairment during electroconvulsive therapy in severely depressed elderly patients. *Am J Geriatr Psychiatry* 2014;**22**:157–166.
 62. ABBOTT CC, LEMKE NT, GOPAL S et al. Electroconvulsive therapy response in major depressive disorder: a pilot functional network connectivity resting state fMRI investigation. *Front Psychiatry* 2013;**4**:10.
 63. WEI Q, TIAN Y, YU Y et al. Modulation of interhemispheric functional coordination in electroconvulsive therapy for depression. *Transl Psychiatry* 2014;**4**:e453.
 64. PERRIN JS, MERZ S, BENNETT DM et al. Electroconvulsive therapy reduces frontal cortical connectivity in severe depressive disorder. *Proc Natl Acad Sci U S A* 2012;**109**:5464–5468.
 65. BEALL EB, MALONE DA, DALE RM et al. Effects of electroconvulsive therapy on brain functional activation and connectivity in depression. *J ECT* 2012;**28**:234–241.
 66. CHRIST M, MICHAEL N, HIHN H et al. Auditory processing of sine tones before, during and after ECT in depressed patients by fMRI. *J Neural Transm (Vienna)* 2008;**115**:1199–1211.
 67. LYDEN H, ESPINOZA RT, PIRNIA T et al. Electroconvulsive therapy mediates neuroplasticity of white matter microstructure in major depression. *Transl Psychiatry* 2014;**4**:e380.
 68. JORGENSEN A, MAGNUSSON P, HANSON LG et al. Regional brain volumes, diffusivity, and metabolite changes after electroconvulsive therapy for severe depression. *Acta Psychiatr Scand* 2016;**133**:154–164.
 69. PENG W, CHEN Z, YIN L, JIA Z, GONG Q. Essential brain structural alterations in major depressive disorder: A voxel-wise meta-analysis on first episode, medication-naïve patients. *J Affect Disord* 2016;**199**:114–123.
 70. FU CHY, COSTAFREDA SG, SANKAR A et al. Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine. *BMC Psychiatry* 2015;**15**:82.
 71. KOZEL FA, JOHNSON KA, NAHAS Z et al. Fractional anisotropy changes after several weeks of daily left high-frequency repetitive transcranial magnetic stimulation of the prefrontal cortex to treat major depression. *J ECT* 2011;**27**:5–10.
 72. PETERCHEV AV, ROSA MA, DENG Z-D, PRUDIC J, LISANBY SH. Electroconvulsive therapy stimulus parameters: rethinking dosage. *J ECT* 2010;**26**:159–174.
 73. SACKEIM HA, PRUDIC J, FULLER R, KEILP J, LAVORI PW, OLFSON M. The cognitive effects of electroconvulsive therapy in community settings. *Neuropsychopharmacology* 2007;**32**:244–254.
 74. SACKEIM HA, PRUDIC J, NOBLER MS et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. *Brain Stimul* 2008;**1**:71–83.
 75. SACKEIM HA, PRUDIC J, DEVANAND DP et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. *N Engl J Med* 1993;**328**:839–846.
 76. SACKEIM HA, PRUDIC J, DEVANAND DP et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. *Arch Gen Psychiatry* 2000;**57**:425–434.
 77. SACKEIM HA. Convulsant and anticonvulsant properties of electroconvulsive therapy: towards a focal form of brain stimulation. *Clin Neurosci Res* 2004;**4**:39–57.
 78. SACKEIM HA, DECINA P, PORTNOY S, NEELEY P, MALITZ S. Studies of dosage, seizure threshold, and seizure duration in ECT. *Biol Psychiatry* 1987;**22**:249–268.
 79. SPELLMAN T, PETERCHEV AV, LISANBY SH. Focal electrically administered seizure therapy: a novel form of ECT illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction. *Neuropsychopharmacology* 2009;**34**:2002–2010.
 80. NAHAS Z, SHORT B, BURNS C et al. A feasibility study of a new method for electrically producing seizures in man: focal electrically administered seizure therapy [FEAST]. *Brain Stimul* 2013;**6**:403–408.
 81. CHAHINE G, SHORT B, SPICER K et al. Regional cerebral blood flow changes associated with focal electrically administered seizure therapy (FEAST). *Brain Stimul* 2014;**7**:483–485.
 82. PÉRAN P, CHERUBINI A, ASSOFGNA F et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. *Brain* 2010;**133**:3423–3433.
 83. PÉRAN P, CHERUBINI A, LUCCICENTI G et al. Volume and iron content in basal ganglia and thalamus. *Hum Brain Mapp* 2009;**30**:2667–2675.
 84. PÉRAN P, HAGBERG G, LUCCICENTI G et al. Voxel-based analysis of R2* maps in the healthy human brain. *J Magn Reson Imaging* 2007;**26**:1413–1420.
 85. CHERUBINI A, PÉRAN P, CALTAGIRONE C, SABATINI U, SPALLETTA G. Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. *NeuroImage* 2009;**48**:29–36.
 86. CHERUBINI A, PÉRAN P, SPOLETINI I et al. Combined volumetry and DTI in subcortical structures of mild cognitive impairment and Alzheimer's disease patients. *J Alzheimers Dis* 2010;**19**:1273–1282.

Yrondi et al.

87. EUSTACHE P, NEMMI F, SAINT-AUBERT L, PARIENTE J, PÉRAN P. multimodal magnetic resonance imaging in Alzheimer's disease patients at prodromal stage. *J Alzheimers Dis* 2016;**50**:1035–1050.
88. SPOLETINI I, CHERUBINI A, BANFI G et al. Hippocampi, thalami, and accumbens microstructural damage in schizophrenia: a volumetry, diffusivity, and neuropsychological study. *Schizophr Bull* 2011;**37**:118–130.
89. CERASA A, CHERUBINI A, PERAN P, CERASA A, CHERUBINI A, PERAN P. Multimodal MRI in neurodegenerative disorders, multimodal MRI in neurodegenerative disorders. *Neurol Res Int* 2011;**2012**:1–2. e287891.